297 results about "Heterocyclic compound" patented technology

Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating cancer.　The present inventors have examined a compound useful as an active ingredient in a pharmaceutical composition for cancer treatment, and have completed the present invention by finding that: a heterocyclic compound represented by formula (I) and formula (I-I) has excellent an action of inducing degradation of a mutant KRAS protein and a wild-type KRAS protein, and in particular, an action of inducing degradation of a KRAS protein having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation; and said heterocyclic compound has mutant KRAS inhibition and the inhibitory activity of KRAS amplified by a wild-type KRAS gene, and in particular, inhibitory activity of KRAS having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for cancer.

The application discloses an electrolyte, a preparation method thereof and a lithium ion battery, and belongs to the technical field of batteries.The electrolyte comprises a lithium salt, a first additive, a second additive and a solvent; the first additive is a compound carrying an isocyanate substituent and a nitrile substituent in a molecular structure; and the second additive is a sulfur-containing heterocyclic compound.The first additive of the electrolyte can remove water and HF in the electrolyte, prevents HF from attacking CEI and causing transition metal dissolution of a ternary positive electrode material and destruction of a material structure; the nitrile substituent has extremely strong complexing force with transition metals, inhibits electrolyte oxidative decomposition and positive electrode transition metal element dissolution; the second additive has the advantages of impedance reduction and gas production inhibition but is prone to generating acidic substances; the first additive has water and acid removal functions and can inhibit the second additive from generating acidic substances; and the synergistic effect of the two additives can improve the compatibility of the electrolyte and the ternary positive electrode material and improve the electrochemical performance of the lithium ion battery.

A heterocyclic compound represented by Formula 1, an organic light-emitting device including the heterocyclic compound, and an electronic apparatus:wherein, in Formula 1,Cz1 is a group represented by Formula 2,k1 to k3 are each independently 0, 1, 2, 3, 4, or 5, and a sum of k1 to k3 is 1 or greater,and wherein the descriptions of the remaining substituents in Formula 1 and Formula 2 are as provided herein.

This invention relates to the field of battery technology, specifically to a negative electrode binder, its preparation method, and its application. The negative electrode binder comprises: a core, wherein the polymer monomers of the core include styrene, butadiene, and heterocyclic compounds; and an ion-conducting network, wherein the ion-conducting network includes branches and a dynamically cross-linked network, wherein the dynamically cross-linked network is a cross-linked structure obtained by coordination reaction between the branches and metal ions, wherein the branches include carboxylic acid-terminated polyethylene glycol and borate ester-terminated polyethylene glycol, and the metal ions include Ca... 2+ Zn 2+ Mg 2+ One or more of the following; the ion-conducting network is grafted onto the core. Compared with the prior art, the present invention improves the mechanical strength and adhesion of the binder through butadiene-styrene doped heterocyclic compound copolymerization, achieves self-healing of the material through the ion-conducting network, maintains the stability of the internal structure of the battery, and extends the service life of the battery.

The present application provides a heterocyclic compound represented by formula 1, an organic light emitting element including the same, and a composition for forming an organic layer.

The present invention provides a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition comprising the compound, and a use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as shown in Formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, or racemate thereof. The compound of the present invention is capable of effectively reducing the synthesis of fatty acids and cholesterol esters, thereby alleviating the development and deterioration of metabolic diseases.

The application discloses a synthesis method of aza-cyclic modified hydroxyalkyl diethanolamine borate linking agent, which comprises the following steps: (1) adding hydroxyalkyl diethanolamine and boric acid into a three-neck flask provided with a stirrer, a thermometer and a vacuum distillation device, and stirring and heating to react until no water is generated; (2) adding an aza-cyclic compound into the reaction system obtained in the step (1), increasing the reaction temperature, and removing water generated in the reaction by vacuum distillation when no water vapor is generated, so as to obtain a target product. The borate linking agent obtained by the synthesis method has good hydrolysis resistance, and when the borate linking agent is used in a hydroxyl-terminated solid propellant, the mechanical properties of the hydroxyl-terminated solid propellant can be effectively improved.

This invention provides heterocyclic compounds having the structure shown in Formula (I), pharmaceutically acceptable salts thereof, or stereoisomers thereof, as well as pharmaceutical compositions and applications thereof. The heterocyclic compounds and their pharmaceutically acceptable salts and isomers provided by this invention can effectively inhibit the activity of RET kinases, including wild-type and various mutant RET kinases, especially G810C and G810R mutant RET kinases, thereby regulating the activation of multiple downstream pathways. These compounds can be used to prepare drugs for the prevention and treatment of various diseases related to abnormal RET kinase expression, such as leukemia and other tumors.

This application belongs to the field of new energy battery technology, specifically relating to a separator and a battery. This application provides a separator, including a base film and a functional layer disposed on at least one surface along the thickness direction of the base film; the functional layer includes barium titanate particles and organic particles, the organic particles comprising nitrogen-containing aromatic heterocyclic compounds; the median volumetric diameter of the barium titanate particles is denoted as D1 μm, and the median volumetric diameter of the organic particles is denoted as D2 μm, satisfying 0.5 ≤ D1 / D2 ≤ 4; the particle size distribution span value of the barium titanate particles is 0.6–1.2; the particle size distribution span value of the organic particles is 0.8–1.5. The separator provided by this application exhibits excellent thermal safety, high-temperature storage, and high-temperature cycling performance, with a significantly improved K-value.

This invention discloses a method for preparing a Schiff base corrosion inhibitor for AZ91D magnesium alloy coolant. The method involves adding an ethanol or acetone solution of the ketone-containing heterocyclic compound dropwise to an aqueous solution of the alkaline amino acid at a molar ratio of 1:1 to 1.5. The reaction is carried out at 40–80°C for 4–36 hours, followed by concentration, extraction with glacial ethyl acetate, washing with glacial ethyl acetate, and drying to obtain the corrosion inhibitor. Further, the corrosion inhibitor is formulated into a coolant specifically for AZ91D magnesium alloy. This coolant is composed of a mixture of raw materials with the following weight percentages: 0.1–2% corrosion inhibitor, 39–60% deionized water, and 39–60% ethylene glycol. This invention features a simple preparation process, and the obtained corrosion inhibitor can be stored for a long time, exhibits good thermal stability, strong oxidation resistance, low conductivity, high corrosion inhibition efficiency, and good corrosion inhibition effect on AZ91D magnesium alloy.

The present invention relates to polymorphs of a nitrogen-containing heterocyclic compound. The polymorphs of the present invention can effectively enhance or reactivate synaptic plasticity, and inhibit or eliminate the accumulation of beta-amyloid, without causing side effects, thereby exerting a therapeutic effect on various nervous system diseases or neurodegenerative diseases. In addition, the polymorphs of the present invention exhibit excellent physicochemical properties, such as stability, solubility, hygroscopicity, and mechanical strength, and show excellent permeability to the blood-brain barrier (BBB).

The application discloses a heterocyclic compound, a pharmaceutical composition thereof, intermediates thereof, and a preparation method and application of the heterocyclic compound. Specifically provided is a compound shown in formula (A) or a pharmaceutically acceptable salt thereof. The compound of the application has one or more of the following effects: (1) the compound has inhibitory activity on Nav1.8; (2) the compound has good solubility; (3) the compound has good analgesic effect; (4) the compound has good pharmacokinetic characteristics; (5) the compound has fast onset; (6) the compound is rapidly absorbed orally; and (7) the compound meets the requirements of injection administration.

The present disclosure provides heterocycle compounds with RIP2 kinase inhibitory activity, pharmaceutical compositions comprising the same, methods using the same and applications thereof. The present disclosure provides compounds of Formula (I), as inhibitors of RIP2 kinase. These compounds can be used for preventing and / or treating RIP2 kinase-related diseases and / or conditions.

This invention belongs to the field of organic electroluminescence technology, specifically relating to a luminescent crystal material, its preparation method and application, and laser-prefabricated luminescent devices. The preparation method of the luminescent crystal material includes the following steps: a first reaction is carried out with an amino-containing spirodifluorene monomer, a halogenated nitrogen heterocyclic compound, and a fluorinated organic acid to obtain a first intermediate; the first intermediate undergoes a second reaction with a gallium halide to obtain a second intermediate; a third reaction is carried out with a carbazole derivative, a naphthenic acid derivative, a luminescent bandgap modulating organic compound, and the second intermediate to obtain a third intermediate; the third intermediate is dissolved in an organic solvent for a fourth reaction, followed by multi-directional condensation separation; the material is collected in a pre-designed receiving dish in a 90-110°C condensation zone, and then subjected to a fourth post-processing to obtain the luminescent crystal material. The prepared luminescent crystal material exhibits high quantum efficiency, excellent thermal stability, and achieves balanced red, green, and blue performance.

The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and / or for treating cancer and other diseases.

The application provides novel N-heterocyclic compounds, such as quinoline or isoquinoline compounds, preferably quinazoline compounds, as calcineurin inhibitors (CNIs,) that provide improved safety profiles, and the pharmaceutical composition and formulation thereof, as well as a method of using the N-heterocyclic compounds for the treatment of, inter alia, an inflammatory-related disease or disorder.

The present application relates to the technical field of synthesis of nitrogen-containing heterocyclic compounds, and particularly relates to a continuous flow synthesis method of nitrogen-containing heterocyclic acetic acid; specifically, nitrogen-containing heterocyclic compounds, halogenated acetic acid ester and inorganic acid binding agent are mixed in an aprotic solvent, and then are introduced into a microchannel of an ultrasonic microchannel continuous flow reactor to perform a substitution reaction under ultrasonic cavitation; after the reaction, the reaction liquid is collected and post-treated to obtain a nitrogen-containing heterocyclic acetic acid ester intermediate; the nitrogen-containing heterocyclic acetic acid ester intermediate is introduced into a second microreactor using an inorganic lye to perform a hydrolysis reaction, and after the reaction, the reaction liquid is collected and post-treated to obtain the nitrogen-containing heterocyclic acetic acid; the present application realizes continuous flow reaction of a heterogeneous system by using emulsification and ultrasonic technology, and can be used for the next step of continuous flow hydrolysis reaction after simple filtration and separation; the present application has high yield of two-step reaction, simple separation, short reaction time, and is suitable for large-scale industrial production.

Provided herein are heterocyclic compounds of Formula (I), Formula (II), Formula (III), Formula (IIIa), Formula (Mb), Formula (IIIc), Formula (Hid), Formula (IV), Formula (IVa), Formula (IVb), and Formula (IVc), and pharmaceutically acceptable salts, tautomers, isotopologues, and stereoisomers thereof, compositions comprising an effective amount of a heterocyclic compound of Formula (I), Formula (II), Formula (III), Formula (IIIa), Formula (Mb), Formula (IIIc), Formula (Hid), Formula (IV), Formula (IVa), Formula (IVb), and Formula (IVc), and methods for treating or preventing heartworm infections and diseases in animals and humans.

The problem to be solved by the present invention is to provide a novel herbicide that is highly safe for crops and has excellent weed-controlling activity against weeds, in order to address the food crisis expected in the near future due to global population growth. This problem is solved by: a compound represented by the following general formula (I): or a salt thereof; an agricultural or horticultural herbicide containing the compound or its salt as an active ingredient; and a method for using the herbicide.

The invention belongs to the technical field of biochemistry, and particularly relates to a method for catalytically synthesizing a chiral nitrogen heterocyclic compound by a biological enzyme. The invention develops a method for obtaining a chiral nitrogen heterocyclic compound with high enantioselectivity by catalyzing an easily-obtained N-acyloxy amine compound as a nazein precursor to carry out C (sp3)-H amination cyclization reaction by taking an enzyme containing heme as a catalyst. The enzyme catalysis method is mild in reaction condition, simple in technical requirement, wide in substrate universality, high in product enantioselectivity and green, efficient and economical in synthesis process. The nitrogen-containing heterocyclic compound prepared by the method disclosed by the invention has the advantages of better reaction yield, excellent regioselectivity, wide substrate range and good functional group compatibility, and can be applied to synthesis and modification of some drug intermediates.

The present invention provides a photosensitive resin composition with improved adhesion to copper after curing. [Solution] A photosensitive resin composition comprising: component (A), which is at least one selected from the group consisting of polyimide and its precursors containing a structural unit represented by the following general formula (1), and polybenzoxazole and its precursors containing a structural unit having a ketone group; a polymerization initiator (B); and an aromatic heterocyclic compound (C) having an amino group. TIFF2026109040000049.tif44153 (In general formula (1), X represents a constituent unit (X) which is a divalent organic group, and Y represents a constituent unit (Y) which is a tetravalent organic group, and the constituent unit (Y) includes a constituent unit (Y-1) which has a ketone group.)

This invention belongs to the field of organic light-emitting materials and semiconductor technology, and provides an asymmetric heterocyclic compound, its preparation method, and an electroluminescent device. The structural formula of the asymmetric heterocyclic compound is as follows. Using the asymmetric heterocyclic compound provided by this invention as the host light-emitting material to prepare an electroluminescent device can effectively improve the luminous performance of the electroluminescent device and extend its service life.

A light-emitting device is provided and including a heterocyclic compound represented by Formula 1, and an electronic apparatus including the light-emitting device:Formula 1 may be understood by referring to the description of Formula 1 provided herein.

This invention relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting element comprising the same.

The present invention relates to nitrogen-containing heterocyclic compounds having a phenyl group and uses thereof. The compounds, according to the present invention, effectively enhance synaptic plasticity without side-effects and thus may exhibit treatment effects for various neurological disorders such as neurodegenerative disease, neurodegenerative pathology, neuropsychiatric disorder, amnesia, cognitive impairment / damage, and extinction learning disorder.

The invention relates to the use of compounds of formula (1) and the pharmaceutical acceptable salts thereof in the preparation of a medicament used to inhibit the production of beta-lactamases by pathogenic bacteria.